Home/Filings/4/0001209191-20-020269
4//SEC Filing

Shreedhar Vijay 4

Accession 0001209191-20-020269

CIK 0001328143other

Filed

Mar 18, 8:00 PM ET

Accepted

Mar 19, 4:24 PM ET

Size

7.9 KB

Accession

0001209191-20-020269

Insider Transaction Report

Form 4
Period: 2020-03-17
Shreedhar Vijay
Chief Commercial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2020-03-17+47,50047,500 total
    Exercise: $2.32Exp: 2030-03-16Common Stock (47,500 underlying)
  • Award

    Common Stock

    2020-03-17+23,75095,000 total
Footnotes (3)
  • [F1]The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 50% of the total number of Restricted Stock Units will vest on January 31, 2021 and the remaining shares will vest in equal amounts on each of March 20, 2021, March 20, 2022, March 20, 2023 and March 20, 2024, subject to Reporting Person's Continuous Service as of each such date.
  • [F2]Includes 2,500 shares acquired pursuant to the issuer's employee stock purchase plan on November 30, 2019.
  • [F3]The Option shares shall vest as follows: 1/48th of the option shares shall vest on April 1, 2020 and 1/48th shall vest monthly thereafter, subject to Reporting Person's Continuous Service as of each such date.

Issuer

Adamas Pharmaceuticals Inc

CIK 0001328143

Entity typeother

Related Parties

1
  • filerCIK 0001778051

Filing Metadata

Form type
4
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 4:24 PM ET
Size
7.9 KB